Mangoceuticals, Inc. (MGRX)
| Market Cap | 6.17M |
| Revenue (ttm) | 755,000 |
| Net Income (ttm) | -9.33M |
| Shares Out | 2.49M |
| EPS (ttm) | -5.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 215,049 |
| Open | 2.520 |
| Previous Close | 2.440 |
| Day's Range | 2.270 - 2.610 |
| 52-Week Range | 2.100 - 16.800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About MGRX
Mangoceuticals, Inc. develops, markets, and sells various men’s wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRI... [Read more]
Financial Performance
In 2023, Mangoceuticals's revenue was $731,493, an increase of 8083.16% compared to the previous year's $8,939. Losses were -$9.21 million, 361.1% more than in 2022.
Financial StatementsNews
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness produc...
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness pro...
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure teleme...
Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and we...
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness pro...
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category
MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health a...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing Exhibit DALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the...
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a leader in men's health and wellness products including erectile dysfunction (ED),...
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and ...
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets
Dallas, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and ...
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
Dallas, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and w...
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications
Formulations to be marketed as “Slim” and “Trim” as an Oral Dissolvable Tablet (ODT) Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a co...
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration
Dallas, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and ...
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and ...
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products
Signifies the first major step towards the application process for the certification of its Mango ED oral dissolvable products by Mexico's health governing agency, COFEPRIS
MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
The Dallas Based, Direct-to-Consumer Telemedicine Company Brings the FDA-Approved Oral Testosterone Replacement Therapy Treatment to the Telehealth Market
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics